Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 5 Waldenstrom Macroglobulinemia 1 Recurrence 1 Precancerous Conditions 1 Neoplasms, Plasma Cell 1 Medulloblastoma 1 Mastocytosis, Systemic 1 Lymphoma, Mantle-Cell 1 Liver Neoplasms 1 Leukemia, Large Granular Lymphocytic 1 Ependymoma 1 Carcinoma, Hepatocellular 1

Interventions

Rituximab 45 Cyclophosphamide 38 ibrutinib 22 fludarabine 22 acalabrutinib 21 venetoclax 20 zanubrutinib 17 Lenalidomide 17 Bendamustine Hydrochloride 17 obinutuzumab 16 fludarabine phosphate 14 Magnetic Resonance Spectroscopy 14 Cytarabine 14 Specimen Handling 13 CT-P10 13 pirtobrutinib 12 Biopsy 12 glofitamab 10 Etoposide 10 Whole-Body Irradiation 9 Vincristine 7 Peripheral Blood Stem Cell Transplantation 7 Mycophenolic Acid 7 Melphalan 7 Doxorubicin 7 brexucabtagene autoleucel 6 Cyclosporine 6 orelabrutinib 5 Methotrexate 5 Immunotherapy, Adoptive 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Mantle-Cell × Thalidomide × 1 year × Clear all

NCT02858804 2026-02-11

BDH-MCL01

Institute of Hematology & Blood Diseases Hospital, China

Phase 4 Completed

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡